Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Zhao, 2021

favipiravir (n=36) vs. standard of care (n=19)

randomized controlled trial   some concerns about risk of bias

Studied treatment

favipiravir
ffavipiravir was 1600 mg (bid) on the first day, and 600 mg (bid) from the 2nd day to the 7th day, orally

Control treatment

standard of care

Patients

preventing respiratory virus transmission

Method

Open-label.

Multicenter, China

Remark